Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Retained Earnings (2024 - 2025)

Historic Retained Earnings for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to -$429.1 million.

  • Xilio Therapeutics' Retained Earnings fell 1576.72% to -$429.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$429.1 million, marking a year-over-year decrease of 1576.72%. This contributed to the annual value of -$383.8 million for FY2024, which is N/A changed from last year.
  • Per Xilio Therapeutics' latest filing, its Retained Earnings stood at -$429.1 million for Q3 2025, which was down 1576.72% from -$412.9 million recorded in Q2 2025.
  • Xilio Therapeutics' 5-year Retained Earnings high stood at -$342.7 million for Q1 2024, and its period low was -$429.1 million during Q3 2025.